↓ Skip to main content

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
3 X users
bluesky
1 Bluesky user

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank
Published in
Urologic Oncology, August 2025
DOI 10.1016/j.urolonc.2025.07.020
Pubmed ID
Authors
Abstract

Accurate prognostication and personalized treatment selection remain major challenges in kidney cancer. This consensus initiative aimed to provide actionable expert guidance on the development and clinical integration of prognostic and predictive biomarkers and risk stratification tools to improve patient care and guide future research. A modified Delphi method was employed to develop consensus statements among a multidisciplinary panel of experts in urologic oncology, medical oncology, radiation oncology, pathology, molecular biology, radiology, outcomes research, biostatistics, industry, and patient advocacy. Over 3 rounds, including an in-person meeting 20 initial statements were evaluated, refined, and voted on. Consensus was defined a priori as a median Likert score ≥8. Nineteen final consensus statements were endorsed. These span key domains including biomarker prioritization (favoring prognostic biomarkers), rigorous methodology for subgroup and predictive analyses, the development of multi-institutional prospective registries, incorporation of biomarkers in trial design, and improvements in data/biospecimen access. The panel also identified high-priority biomarker types (e.g., AI-based image analysis, ctDNA) for future research. This is the first consensus statement specifically focused on biomarker and risk model development for kidney cancer using a structured Delphi process. The recommendations emphasize the need for rigorous methodology, collaborative infrastructure, prospective data collection, and focus on clinically translatable biomarkers. The resulting framework is intended to guide researchers, cooperative groups, and stakeholders in advancing personalized care for patients with kidney cancer.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 2 33%
Other 1 17%
Unknown 3 50%
Readers by discipline
Readers by discipline Count As %
Immunology and Microbiology 1 17%
Medicine and Dentistry 1 17%
Unknown 4 67%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2026.
All research outputs
#21,459,461
of 34,575,175 outputs
Outputs from Urologic Oncology
#1,664
of 2,931 outputs
Outputs of similar age
#115,134
of 342,017 outputs
Outputs of similar age from Urologic Oncology
#8
of 20 outputs
Altmetric has tracked 34,575,175 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,931 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,017 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.